ORENCIA 250 mg/15mL

Abatacept, the active ingredient in ORENCIA, is a selective T-cell costimulation modulator presented as a 250 mg/15 mL lyophilized powder for intravenous use. It is used to treat moderate-to-severe rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis in patients who have not responded to other treatments.

GNH USA supplies ORENCIA as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

ORENCIA is a selective co-stimulation modulator used to treat autoimmune and inflammatory conditions.

- Rheumatoid arthritis: Reduces signs and symptoms, slows joint damage, and improves joint function in adults who have not responded to other DMARDs or TNF antagonists. - Juvenile idiopathic arthritis: Treats moderate-to-severe active juvenile idiopathic arthritis in children aged 6 years and older who have not responded to DMARDs. - Psoriatic arthritis: Treats active psoriatic arthritis in adults who have had an inadequate response to other DMARDs. - Graft-vs-host disease: Used in combination with other medications to prevent GVHD in people who have had a stem cell transplant.

ORENCIA may cause side effects, ranging from common to serious.

Common Side Effects: - Headache - Nausea - Upper respiratory tract infection - Nasopharyngitis - Infusion-related reactions - Dizziness - Diarrhea - Fatigue

Serious or Rare Side Effects: - Increased risk of infections - Serious infections, including opportunistic infections - Hypersensitivity reactions - Gastrointestinal perforations - Blood disorders, such as lymphopenia and neutropenia - Increased risk of malignancies

ORENCIA should be used with caution and under medical supervision.

- Inform your healthcare provider if you have any infections: ORENCIA can increase the risk of infections. - Avoid live vaccines: Do not receive live vaccines while using ORENCIA. - Monitor for signs of infection: Regularly check for symptoms of infection. - Use with caution in patients with chronic obstructive pulmonary disease: May increase the risk of COPD exacerbations. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

ORENCIA may interact with other medications, requiring careful monitoring.

Major Interactions (Avoid): - Live vaccines: Avoid concurrent use due to increased risk of infections. - Biologic DMARDs: Avoid concurrent use with other biologic DMARDs.

Moderate Interactions (Monitor Closely): - Immunosuppressants: Monitor for increased risk of infections and immunosuppression. - Corticosteroids: Monitor for increased risk of infections and adverse effects. - TNF antagonists: Monitor for increased risk of infections and adverse effects.